Q3 EPS Estimate for Caribou Biosciences Increased by Analyst

Caribou Biosciences, Inc. (NASDAQ:CRBU) – HC Wainwright boosted their Q3 2026 EPS estimates for shares of Caribou Biosciences in a research note issued to investors on Thursday, October 8th. HC Wainwright analyst R. Burns now forecasts that the company will earn ($0.25) per share for the quarter, up from their previous estimate of ($0.32). HC Wainwright has a “Neutral” rating on the stock. The consensus estimate for Caribou Biosciences’ current full-year earnings is ($1.07) per share. HC Wainwright also issued estimates for Caribou Biosciences’ Q4 2026 earnings at ($0.29) EPS, FY2026 earnings at ($1.04) EPS and FY2027 earnings at ($0.32) EPS.

Caribou Biosciences (NASDAQ:CRBU) last issued its earnings results on Thursday, August 13th. The company reported ($0.24) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.32) by $0.08. Caribou Biosciences had a negative net margin of 1,030.42% and a negative return on equity of 89.11%. The company had revenue of $1.50 million during the quarter, compared to analyst estimates of $2.28 million.

A number of other analysts have also recently issued reports on CRBU. Brookline Capital Markets cut Caribou Biosciences from a “buy” rating to a “hold” rating in a research report on Wednesday, October 7th. Royal Bank Of Canada lowered Caribou Biosciences from an “outperform” rating to a “sector perform” rating and set a $1.00 target price on the stock. in a research report on Wednesday, October 7th. Bank of America dropped their target price on Caribou Biosciences from $6.00 to $5.00 and set a “buy” rating on the stock in a research report on Friday, August 14th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Caribou Biosciences in a research note on Friday, July 17th. Finally, Wall Street Zen downgraded Caribou Biosciences from a “hold” rating to a “sell” rating in a research note on Saturday, September 19th. One analyst has rated the stock with a Strong Buy rating, two have issued a Buy rating, four have issued a Hold rating and one has issued a Sell rating to the company. According to MarketBeat.com, the stock currently has an average rating of “Hold” and an average target price of $5.50.

Caribou Biosciences Trading Down 5.4%

NASDAQ CRBU opened at $0.47 on Monday. Caribou Biosciences has a 1-year low of $0.44 and a 1-year high of $3.54. The firm’s fifty day simple moving average is $1.37 and its 200-day simple moving average is $1.71. The company has a market capitalization of $50.39 million, a PE ratio of -0.44 and a beta of 2.31.

Institutional Inflows and Outflows

Several hedge funds have recently modified their holdings of CRBU. CTC Alternative Strategies Ltd. acquired a new position in shares of Caribou Biosciences during the first quarter valued at about $29,000. Westmount Partners LLC bought a new stake in shares of Caribou Biosciences in the first quarter valued at about $37,000. Next Capital Management LLC acquired a new stake in Caribou Biosciences during the second quarter worth about $35,000. The Manufacturers Life Insurance Company acquired a new stake in Caribou Biosciences during the second quarter worth about $41,000. Finally, Spark Investment Management LLC acquired a new stake in Caribou Biosciences during the second quarter worth about $42,000. Institutional investors and hedge funds own 77.51% of the company’s stock.

Caribou Biosciences Company Profile

Caribou Biosciences, Inc is a clinical-stage biotechnology company developing genome-edited cell therapies for cancer and other serious diseases. The company uses its proprietary CRISPR-based chRDNA genome-editing platform to engineer immune cells, with an emphasis on allogeneic, or “off-the-shelf,” CAR-T therapies designed to target tumors without requiring cells to be collected from each individual patient.

Caribou’s research and development programs have focused primarily on hematologic malignancies, including investigational CAR-T candidates directed at targets such as CD19 and BCMA.